The round pushed the overall funding for Stanford's autoimmune and neurodegenerative disorder drug developer past $250m.
Annexon, a US-based biopharmaceutical spinout of Stanford University, completed a $100m financing round yesterday led by hedge fund manager Redmile Group.
Deerfield Management, Eventide Asset Management, Farallon Capital Management, Janus Henderson Investors and Logos Capital also took part in the round as new investors, along with funds and accounts managed by BlackRock.
The round was filled out by existing shareholders Adage Capital Partners, Bain Capital Life Sciences, Blackstone Life Sciences, New Enterprise Associates (NEA), Satter Medical Technology Partners and Surveyor Capital.
Founded in 2011, Annexon is developing treatments for body, brain and eye disorders caused by the aberrant activation of a molecule in the immune system called C1q which can lead to autoimmune and neurodegenerative diseases.
Douglas Love, Annexon’s president and CEO, said: “We are very pleased to have such a strong investor group supporting our team, unique platform and deep pipeline of product candidates for…
